切除输卵管能否有效降低卵巢癌风险

卵巢癌是澳大利亚女性第九大常见癌症，普通女性终身患病风险为1%1。然而对于携带BRCA1基因突变的女性，这一风险高达44%；携带BRCA2基因突变的女性风险为17%1。针对这一健康威胁，医学界正在重新审视一项可能的预防策略——在进行其他手术时同步切除输卵管。

研究证据表明，切除输卵管（而非卵巢本身）可能具有显著的预防效果。2015年的瑞典研究发现，接受输卵管切除的女性卵巢癌患病风险降低约60%1。2023年的国际证据综述则报告该手术基于建模可将风险降低80%，但实际临床研究证据表明风险降低约50%1。重要的是，输卵管切除通常只增加手术时间5至15分钟，不会增加并发症风险，且不导致早期更年期1。

基于这些发现，美国、加拿大、欧洲及国际妇产科联合会已推荐机会性输卵管切除术1。澳大利亚皇家妇产科学院在2023年的指南中建议，在进行子宫切除或作为输卵管结扎的替代方案时，应向患者提供该手术选项1。然而，澳大利亚目前尚未将此列为常规医疗程序，且医疗保险计划Medicare并不覆盖该手术费用1。医学界认为需要更多长期研究证据来支持这一预防措施的广泛实施1。

Ovarian cancer represents the ninth most common cancer affecting women in Australia, with women in the general population facing a 1% lifetime risk of developing the disease 1. However, the risk is substantially higher for carriers of specific genetic mutations: women with the BRCA1 gene variant face a 44% lifetime risk, while those carrying BRCA2 have a 17% risk 1. Research increasingly suggests that fallopian tube removal may offer a meaningful preventive strategy for reducing ovarian cancer incidence.

A 2015 Swedish study found that women who underwent fallopian tube removal experienced approximately a 60% reduction in ovarian cancer risk 1. More recent evidence indicates potentially greater protective benefit; a 2023 international evidence review reported risk reductions of up to 80%, though this figure is based on mathematical modeling rather than clinical trials, with actual clinical evidence demonstrating risk reductions of approximately 50% 1. The procedure itself imposes minimal surgical burden, typically adding only 5 to 15 minutes to operation time without increasing the risk of complications 1.

Professional medical organizations internationally have begun endorsing opportunistic fallopian tube removal. The American, Canadian, and European gynecological associations, along with the International Federation of Gynaecology and Obstetrics, have recommended the procedure 1. Australia's Royal Australian and New Zealand College of Obstetricians and Gynaecologists released 2023 guidelines recommending that the option be offered to women undergoing hysterectomy or considering the procedure as an alternative to tubal ligation 1. Despite this growing consensus, Australia has not yet adopted fallopian tube removal as a routine surgical procedure, and the country's Medicare system does not currently provide coverage for the operation 1. Continued long-term research evidence is needed to support broader clinical implementation 1.